- Home
- CHRS vs BHST Comparison
CHRS vs BHST Comparison
Compare CHRS & BHST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHRS
- BHST
- Stock Information
- Founded
- CHRS 2010
- BHST 2007
- Country
- CHRS United States
- BHST Canada
- Employees
- CHRS N/A
- BHST N/A
- Industry
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- BHST
- Sector
- CHRS Health Care
- BHST
- Exchange
- CHRS Nasdaq
- BHST Nasdaq
- Market Cap
- CHRS 112.5M
- BHST 106.0M
- IPO Year
- CHRS 2014
- BHST N/A
- Fundamental
- Price
- CHRS $0.76
- BHST $7.20
- Analyst Decision
- CHRS Buy
- BHST Strong Buy
- Analyst Count
- CHRS 3
- BHST 2
- Target Price
- CHRS $4.68
- BHST $13.00
- AVG Volume (30 Days)
- CHRS 1.2M
- BHST 12.5K
- Earning Date
- CHRS 08-07-2025
- BHST 05-15-2025
- Dividend Yield
- CHRS N/A
- BHST N/A
- EPS Growth
- CHRS N/A
- BHST N/A
- EPS
- CHRS N/A
- BHST N/A
- Revenue
- CHRS $272,251,000.00
- BHST $27,704,000.00
- Revenue This Year
- CHRS N/A
- BHST $116.40
- Revenue Next Year
- CHRS $132.69
- BHST $55.91
- P/E Ratio
- CHRS $1.79
- BHST N/A
- Revenue Growth
- CHRS 19.87
- BHST 74.76
- 52 Week Low
- CHRS $0.66
- BHST $4.66
- 52 Week High
- CHRS $2.43
- BHST $7.86
- Technical
- Relative Strength Index (RSI)
- CHRS 40.42
- BHST N/A
- Support Level
- CHRS $0.74
- BHST N/A
- Resistance Level
- CHRS $0.90
- BHST N/A
- Average True Range (ATR)
- CHRS 0.05
- BHST 0.00
- MACD
- CHRS 0.01
- BHST 0.00
- Stochastic Oscillator
- CHRS 13.56
- BHST 0.00
About CHRS Coherus BioSciences Inc.
Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. The company is focused on the research, development, and commercialization of its portfolio of FDA-approved oncology products, including LOQTORZI. The company markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The company generates revenue from the United States.
About BHST BioHarvest Sciences Inc. Common Stock
BioHarvest Sciences Inc is the developer and owner of the patented bio-cell growth platform farming technology. This company is the industrial large-scale plant cell growth technology capable of directly and constantly producing active plant ingredients without the necessity to grow the plant itself. The company is focused on leveraging its botanical synthesis technology to develop the next generation of science-based and clinical therapeutic solutions, within two business verticals - nutraceutical health and wellness products such as dietary supplements, and the development of plant cell-based Active Pharmaceutical Ingredients (APIs) that focus on specific medical indications.